pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer

References

• Alexis F, Pridgen E, Molnar LK, et al. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–15.
   PubMed Web of Science ®Google Scholar
• Andersson ER, Sandberg R, Lendahl U. (2011). Notch signaling: simplicity in design, versatility in function. Development 138:3593–612.
   PubMed Web of Science ®Google Scholar
• Arasada RR, Amann JM, Rahman MA, et al. (2014). EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res 74:5572–84.
   PubMed Web of Science ®Google Scholar
• Baker AT, Zlobin A, Osipo C. (2014). Notch-EGFR/HER2 bidirectional crosstalk in breast cancer. Front Oncol 4:360.
   PubMedGoogle Scholar
• Baselga J, Arteaga CL. (2005). Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445–59.
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, et al. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negativeinvasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–8.
   PubMed Web of Science ®Google Scholar
• Brinkman AM, Chen G, Wang Y, et al. (2016). Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials 101:20–31.
   PubMed Web of Science ®Google Scholar
• Chen JQ, Russo J. (2009). ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 1796:162–75.
   PubMed Web of Science ®Google Scholar
• Corkery B, Crown J, Clynes M, O'Donovan N. (2009). Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20:862–7.
   PubMed Web of Science ®Google Scholar
• Crown J, O'Shaughnessy J, Gullo G. (2012). Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 23:56–65.
   PubMed Web of Science ®Google Scholar
• Efferth T. (2012). Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. CMC 19:5735–44.
   PubMed Web of Science ®Google Scholar
• Farnie G, Clarke RB. (2007). Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 3:169–75.
   PubMed Web of Science ®Google Scholar
• Feng X, Yao J, Gao X, et al. (2015). Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry, tumor neovasculature, and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces 7:27885–99.
   PubMed Web of Science ®Google Scholar
• Feng X, Yao J, Gao X, et al. (2017). Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry, tumor neovasculature, and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces 7:27885–99.
   Web of Science ®Google Scholar
• Gao H. (2016). Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6:268–86.
   PubMed Web of Science ®Google Scholar
• Gao H. (2017). Perspectives on dual targeting delivery systems for brain tumors. J Neuroimmune Pharmacol 12:6–16.
   PubMed Web of Science ®Google Scholar
• Giró-Perafita A, Palomeras S, Lum DH, et al. (2016). Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer. Clin Cancer Res 22:4687–97.
   PubMed Web of Science ®Google Scholar
• Hu C, Cun X, Ruan S, et al. (2018). Enzyme-triggered size shrink and laser-enhanced NO release nanoparticles for deep tumor penetration and combination therapy. Biomaterials 168:64–75.
   PubMed Web of Science ®Google Scholar
• Kulkarni SA, Feng SS. (2013). Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res 30:2512–22.
   PubMed Web of Science ®Google Scholar
• Li J, Chen L, Liu N, et al. (2016). EGF-coated nano-dendriplexes for tumor-targeted nucleic acid delivery in vivo. Drug Deliv 23:1718–25.
   PubMed Web of Science ®Google Scholar
• Liao MJ, Ye MN, Zhou RJ, et al. (2014). Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts. Evid Based Complement Alternat Med 2014:628712.
   PubMed Web of Science ®Google Scholar
• Liu CY, Huang TT, Huang CT, et al. (2017). EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. Eur J Cancer 72:112–23.
   PubMed Web of Science ®Google Scholar
• Liu R, Xiao W, Hu C, et al. (2018a). Theranostic size-reducible and no donor conjugated gold nanocluster fabricated hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis. J Control Release 278:127–39.
   PubMed Web of Science ®Google Scholar
• Liu R, Hu C, Yang Y, et al. (2018b). Theranostic nanoparticles with tumor-specific enzyme-triggered size reduction and drug release to perform photothermal therapy for breast cancer treatment. Acta Pharm Sin B Online.
   Google Scholar
• Masuda H, Zhang D, Bartholomeusz C, et al. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136:331–45.
   PubMed Web of Science ®Google Scholar
• Nowacka-Zawisza M, Krajewska WM. (2013). Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches. Postepy Hig Med Dosw (Online) 67:1090–7.
   PubMedGoogle Scholar
• Palma G, Frasci G, Chirico A, et al. (2015). Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 6:26560–74.
   PubMed Web of Science ®Google Scholar
• Pitner MK, Taliaferro JM, Dalby KN, et al. (2017). MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opin Ther Targets 21:849–59.
   PubMed Web of Science ®Google Scholar
• Porkka K, Laakkonen P, Hoffman JA, et al. (2002). A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 99:7444–9.
   PubMed Web of Science ®Google Scholar
• Quan X, Gao H, Wang Z, et al. (2018). Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer. Oncol Lett 15:2131–8.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Kalyana-Sundaram S, Wu YM, et al. (2011). Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 17:1646–51.
   PubMed Web of Science ®Google Scholar
• Ruan S, Xiao W, Hu C, et al. (2017). Ligand-mediated and enzyme-directed precise targeting and retention for the enhanced treatment of glioblastoma. ACS Appl Mater Interfaces 9:20348–60.
   PubMed Web of Science ®Google Scholar
• Shi M, Ma F, Liu J, et al. (2017). A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy. Breast Cancer Res Treat 166:109–16.
   PubMed Web of Science ®Google Scholar
• Simberg D, Duza T, Park JH, et al. (2007). Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 104:932–6.
   PubMed Web of Science ®Google Scholar
• Song Y, Huang Z, Xu J, et al. (2014). Multimodal SPION-CREKA peptide based agents for molecular imaging of microthrombus in a rat myocardial ischemia-reperfusion model. Biomaterials 35:2961–70.
   PubMed Web of Science ®Google Scholar
• Xiao W, Ruan S, Yu W, et al. (2017). Normalizing tumor vessels to increase the enzyme-induced retention and targeting of gold nanoparticle for breast cancer imaging and treatment. Mol Pharm 14:3489–98.
   PubMed Web of Science ®Google Scholar
• Yan J, Wang Y, Jia Y, et al. (2017). Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. Biomed Pharmacother 88:374–83.
   PubMed Web of Science ®Google Scholar
• Yang S, Gao H. (2017). Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res 126:97–108.
   PubMed Web of Science ®Google Scholar